about Zydus | contact us | home       

Welcome to Zydus Pharmaceuticals

Zydus Warfarin Sodium is a generic prescription medication that has been approved by the FDA and is bioequivalent to Coumadin®*. Warfarin, an anticoagulant, is a drug used to reduce the risk of abnormal or dangerous blood clots.

The information provided within this website is a helpful resource to patients, caregivers, pharmacists, and healthcare providers alike to help understand and manage anticoagulation therapy.

This information is an additional resource and does not replace the advice of your healthcare provider. Please see complete prescribing information for additional information.


Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur during the starting period and with a higher dose (resulting in a higher INR). Risk factors for bleeding include high intensity of anticoagulation (INR >4.0), age ≥65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see PRECAUTIONS in full prescribing information), and long duration of warfarin therapy. Regular monitoring of INR should be performed on all treated patients. Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shorter duration of therapy. Patients should be instructed about prevention measures to minimize risk of bleeding and to report immediately to physicians signs and symptoms of bleeding (see PRECAUTIONS in full prescribing information).

Anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater that the potential clinical benefits of anticoagulation, such as: in women who are or may become pregnant, because Warfarin may cause fatal hemorrhage to the fetus and reports of birth malformations; recent or contemplated surgery of the central nervous system, eye or traumatic surgery with large open surfaces; bleeding tendencies associated with active ulceration; threatened abortion, inadequate laboratory facilities; unsupervised patients; spinal puncture.


Please refer to the full package insert for complete prescribing information.

Coumadin® is a registered trademark of Bristol-Myers Squibb Company

Healthcare Providers Patient Information Pharmacist Information FAQs
  About Zydus Contact Us    
Copyright © 2006 Zydus Pharmaceuticals (USA) Inc. All rights reserved.











DHTML Menu / JavaScript Menu - Created Using NavStudio (OpenCube Inc.)